Alex Forum 2025 – Meeting Summary (Nov. 29–30, Taipei)

The two-day Alex Forum gathered Taiwan’s leading lung-cancer specialists to discuss the evolving treatment landscape of ALK-positive and other NSCLC subtypes.

Day 1 focused on advances in ALK+ NSCLC therapy, from optimizing overall survival and post-surgical management with insights from the ALINA study, to tackling resistance mechanisms and exploring immunotherapy combinations in stage III and SCLC settings. Presentations emphasized long-term outcomes and strategies to overcome clinical challenges.